JPWO2021239812A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021239812A5 JPWO2021239812A5 JP2022572753A JP2022572753A JPWO2021239812A5 JP WO2021239812 A5 JPWO2021239812 A5 JP WO2021239812A5 JP 2022572753 A JP2022572753 A JP 2022572753A JP 2022572753 A JP2022572753 A JP 2022572753A JP WO2021239812 A5 JPWO2021239812 A5 JP WO2021239812A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- cell
- less
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 229920001184 polypeptide Polymers 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 229960004641 rituximab Drugs 0.000 claims 9
- 230000027455 binding Effects 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 5
- 230000003834 intracellular effect Effects 0.000 claims 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 4
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 claims 4
- 108091008874 T cell receptors Proteins 0.000 claims 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 108700019146 Transgenes Proteins 0.000 claims 3
- 108700010039 chimeric receptor Proteins 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000006306 Antigen Receptors Human genes 0.000 claims 2
- 108010083359 Antigen Receptors Proteins 0.000 claims 2
- 108091035707 Consensus sequence Proteins 0.000 claims 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 210000003289 regulatory T cell Anatomy 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- -1 CD86 Proteins 0.000 claims 1
- 102100037904 CD9 antigen Human genes 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 102100025390 Integrin beta-2 Human genes 0.000 claims 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000009172 cell transfer therapy Methods 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2007842.4 | 2020-05-26 | ||
| GBGB2007842.4A GB202007842D0 (en) | 2020-05-26 | 2020-05-26 | Polypeptide useful in adoptive cell therapy |
| PCT/EP2021/064053 WO2021239812A1 (en) | 2020-05-26 | 2021-05-26 | Polypeptide useful in adoptive cell therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023527049A JP2023527049A (ja) | 2023-06-26 |
| JPWO2021239812A5 true JPWO2021239812A5 (hr) | 2024-05-29 |
Family
ID=71406309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022572753A Pending JP2023527049A (ja) | 2020-05-26 | 2021-05-26 | 養子細胞療法に有用なポリペプチド |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230183311A1 (hr) |
| EP (1) | EP4157318A1 (hr) |
| JP (1) | JP2023527049A (hr) |
| CN (1) | CN115955977A (hr) |
| AU (1) | AU2021279184A1 (hr) |
| CA (1) | CA3179441A1 (hr) |
| GB (2) | GB202007842D0 (hr) |
| TW (1) | TW202210503A (hr) |
| WO (1) | WO2021239812A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023047098A2 (en) | 2021-09-21 | 2023-03-30 | Quell Therapeutics Ltd | Anti-p75ntr chimeric antigen receptor |
| WO2023047100A1 (en) | 2021-09-21 | 2023-03-30 | Quell Therapeutics Ltd | Anti-trem2 chimeric antigen receptor |
| GB202117298D0 (en) | 2021-11-30 | 2022-01-12 | Quell Therapeutics Ltd | Signalling protein |
| WO2023111594A1 (en) | 2021-12-17 | 2023-06-22 | Quell Therapeutics Limited | Anti-thymocyte globulin for immunomodulation of a subject with regulatory t cells |
| AU2022422880A1 (en) | 2021-12-22 | 2024-05-30 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| WO2023180690A1 (en) | 2022-03-22 | 2023-09-28 | Quell Therapeutics Limited | Methods and products for culturing t cells and uses thereof |
| WO2023215416A1 (en) * | 2022-05-04 | 2023-11-09 | Earli Inc. | Methods using surface-expressable activatable epitopes to localize and/or treat diseased cells |
| GB202217541D0 (en) | 2022-11-24 | 2023-01-11 | Quell Therapeutics Ltd | Recombinant receptor |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
| AU2004252465A1 (en) | 2003-06-13 | 2005-01-06 | Oncomax Acquisition Corp. | Preparation and application of anti-tumor bifunctional fusion proteins |
| US7700097B2 (en) | 2003-06-27 | 2010-04-20 | Biogen Idec Ma Inc. | Purification and preferential synthesis of binding molecules |
| BRPI0610203A2 (pt) | 2005-05-24 | 2010-06-01 | Avestha Gengraine Tech Pvt Ltd | processo de preparação in vivo de anti-corpo monoclonal anti-cd 20 biologicamente ativo e composição farmacêutica |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| GB201415344D0 (en) * | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Protein |
| US10604586B2 (en) | 2016-05-09 | 2020-03-31 | Industrial Technology Research Institute | Humanized monoclonal antibody and uses thereof |
| AU2019250692A1 (en) * | 2018-04-13 | 2020-11-05 | Sangamo Therapeutics France | Chimeric antigen receptor specific for Interleukin-23 receptor |
| GB201814203D0 (en) | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
-
2020
- 2020-05-26 GB GBGB2007842.4A patent/GB202007842D0/en not_active Ceased
-
2021
- 2021-05-26 GB GB2218768.6A patent/GB2611448A/en active Pending
- 2021-05-26 CA CA3179441A patent/CA3179441A1/en active Pending
- 2021-05-26 WO PCT/EP2021/064053 patent/WO2021239812A1/en unknown
- 2021-05-26 TW TW110118988A patent/TW202210503A/zh unknown
- 2021-05-26 US US17/926,374 patent/US20230183311A1/en active Pending
- 2021-05-26 CN CN202180047478.8A patent/CN115955977A/zh active Pending
- 2021-05-26 JP JP2022572753A patent/JP2023527049A/ja active Pending
- 2021-05-26 EP EP21728234.2A patent/EP4157318A1/en active Pending
- 2021-05-26 AU AU2021279184A patent/AU2021279184A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI817302B (zh) | 改良的雙特異性多肽分子 | |
| GB2611448A (en) | Polypeptide useful in adoptive cell therapy | |
| JP6936497B2 (ja) | 多価Ｆｖ抗体 | |
| KR102174280B1 (ko) | 키메라 항원 수용체 | |
| EP3472205B1 (en) | Chimeric antigen receptor | |
| AU2019205273B2 (en) | Multi-domain immunomodulatory proteins and methods of use thereof | |
| JP2017527310A5 (hr) | ||
| KR20220025698A (ko) | 다기능 융합 단백질 및 이의 용도 | |
| JPWO2021239812A5 (hr) | ||
| RU2815388C2 (ru) | Многофункциональные слитые белки и их применения | |
| JPWO2020081988A5 (hr) | ||
| KR102639592B1 (ko) | 짝짓기가 향상된 t 세포 수용체 | |
| WO2022026577A4 (en) | Chimeric t cell receptors, nucleic acids, and methods of making and using the same | |
| EA043129B1 (ru) | Усовершенствованная молекула полипептида с двойной специфичностью | |
| JPWO2021252358A5 (hr) | ||
| JPWO2020168298A5 (hr) |